AMSBIO launches ready-to-use hiPSC-derived cells for medical research
AMSBIO introduces pre-differentiated human induced Pluripotent Stem Cell (hiPSC)-derived cells, offering researchers fully functional cardiomyocytes, hepatocytes and neurons without time-consuming in-house differentiation procedures, potentially transforming research workflows and accelerating discovery timelines.
Streamlined research applications
The newly launched range of hiPSC-derived cells comes fully differentiated and available in high-purity formats, eliminating the need for researchers to perform time-consuming cell differentiation protocols. This advancement particularly benefits Contract Research Organisations (CROs) and life science laboratories by reducing preparation time and optimisation expenses. AMSBIO’s cells undergo functional validation before distribution, allowing researchers to apply them directly to experimental assays without additional validation steps. This streamlined approach helps laboratories optimise their workflows and focus resources on core research objectives rather than cell preparation.
Consistency for reliable outcomes
A notable feature of these hiPSC-derived cells is their exceptional batch-to-batch consistency, which helps ensure reliable experimental outcomes. This consistency makes them particularly valuable for applications requiring reproducible results across multiple experiments. The cells provide physiologically relevant alternatives to primary cells and animal models, offering researchers a scalable and ethically advantageous source of human cells for drug discovery, disease modelling and toxicity screening applications.
Expanded capabilities
AMSBIO, now part of the Europa Biosite group, contributes to scientific discovery through its extensive expertise in extra-cellular matrices and 3D culture systems. The company specialises in tailoring cell systems to enhance organoid and spheroid screening outcomes, including organ-on-a-chip microfluidics.
Beyond their hiPSC-derived cell offerings, AMSBIO provides assays, recombinant proteins and cell lines for drug discovery research. The company maintains a comprehensive biorepository of human and animal tissue specimens, including custom procurement services, and offers clinical-grade products for stem cell and cell therapy applications.
For more information, visit: https://www.amsbio.com/stem-cells/ipsc-derived-cells
Digital issue: Please click here for more information
